Reslizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody therapy, approved by the Food and Drug Administration (FDA) for adults with severe asthma with eosinophilic phenotype, which is a result of eosinophil proliferation [3]. This evidence concerns the gene IL5 and asthma.